https://www.prnewswire.com/news-releases/inmagene-and-kissei-enter-into-an-exclusive-license-agreement-for-fostamatinib-in-china-301345936.html
Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China
/PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and Kissei Pharmaceutical Co., Ltd. ("Kissei") announced today that they have entered into an...
exclusive license agreement